Radiofrequency Ablation in a Patient with Primary Hyperparathyroidism

  • Ayşe Kubat Üzüm
  • Gülşah Yenidünya Yalın
  • Arzu Poyanlı


The most common cause of hypercalcemia and high plasma PTH levels is primary hyperparathyroidism (PHPT). Clinical features are associated with recurrent urolithiasis and osteoporosis. However, most of the patients are generally asymptomatic or have nonspecific complaints. Biochemical diagnosis is based on elevated plasma calcium and parathormone levels and high 24-h urine calcium excretion. The definitive treatment of PHPT is performing parathyroidectomy after the localization of parathyroid adenoma. In patients who are ineligible for surgery (due to comorbidities or surgical risk), management of hypercalcemia can be very challenging, and several medical agents such as bisphosphonates, calcitonin, or cinacalcet are being applied periodically to control high plasma calcium levels. Radiofrequency ablation is a minimally invasive ablation method which is generally used in the management of benign thyroid nodules for volume reduction and improvement of associated symptoms. Lately, this method has also been used in the management of PHPT patients when surgery is not eligible either because of contraindication due to high surgical risk or patient refusal. We hereby present our experience with radiofrequency ablation therapy in the management of hyperparathyroidism in a 59-year-old female patient.


Radiofrequency ablation Primary hyperparathyroidism Parathyroid adenoma 


  1. 1.
    Lafferty FW. Differential diagnosis of hypercalcemia. J Bone Miner Res. 1991;6:51–9.CrossRefGoogle Scholar
  2. 2.
    Bilezikian JP. Clinical review: management of hypercalcemia. J Clin Endocrinol Metab. 1993;77:1445–9.PubMedGoogle Scholar
  3. 3.
    Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int. 2008;74:1385–93.CrossRefGoogle Scholar
  4. 4.
    Marcocci C, Bollerslev J, Khan AA, Shoback DM. Medical management of primary hyperparathyroidism: proceedings of the fourth international workshop on the management of asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab. 2014;99:3607–18.CrossRefGoogle Scholar
  5. 5.
    Silverberg SJ, Bone HG, Marriott TB. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med. 1997;337:1506–10.CrossRefGoogle Scholar
  6. 6.
    Douketis JD, Foster GA, Crowther MA. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med. 2000;160:3431–6.CrossRefGoogle Scholar
  7. 7.
    Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997;336:1506–11.CrossRefGoogle Scholar
  8. 8.
    Fuller CW, Nguyen SA, Lohia S, et al. Radiofrequency ablation for treatment of benign thyroid nodules: systematic review. Laryngoscope. 2014;124:346–53.CrossRefGoogle Scholar
  9. 9.
    Sormaz IC, Poyanlı A, Açar S, İşcan AY, Ozgur I, Tunca F, et al. The results of ultrasonography-guided percutaneous radiofrequency ablation in hyperparathyroid patients in whom surgery is not feasible. Cardiovasc Intervent Radiol. 2017;40:596–602.CrossRefGoogle Scholar
  10. 10.
    Kim BS, Eom TI, Kang KH, et al. Radiofrequency ablation of parathyroid adenoma in primary hyperparathyroidism. J Med Ultrason. 2014;41:239–43.CrossRefGoogle Scholar
  11. 11.
    Wei CH, Harari A. Parathyroid carcinoma: update and guidelines for management. Curr Treat Options Oncol. 2012;13:11–23.CrossRefGoogle Scholar
  12. 12.
    Bae JH, Choi HJ, Lee Y. Preoperative predictive factors for parathyroid carcinoma in patients with primary hyperparathyroidism. J Korean Med Sci. 2012;27:890–5.CrossRefGoogle Scholar
  13. 13.
    Ruda JM, Hollenbeak CS, Stack BC Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg. 2005;132:359–72.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Ayşe Kubat Üzüm
    • 1
  • Gülşah Yenidünya Yalın
    • 2
  • Arzu Poyanlı
    • 3
  1. 1.Division of Endocrinology and Metabolism, Department of Internal Medicine, Istanbul Faculty of MedicineIstanbul UniversityIstanbulTurkey
  2. 2.Department of EndocrinologyBaskent University Istanbul HospitalIstanbulTurkey
  3. 3.Radiology and Interventional RadiologyIstanbul Medical FacultyIstanbulTurkey

Personalised recommendations